keyword
MENU ▼
Read by QxMD icon Read
search

Metastatic pancreatic cancer

keyword
https://www.readbyqxmd.com/read/29038348/stk33-promotes-growth-and-progression-of-pancreatic-cancer-as-a-critical-downstream-mediator-of-hif-1%C3%AE
#1
Fanyang Kong, Xiangyu Kong, Yiqi Du, Ying Chen, Xuan Deng, Jianwei Zhu, Jiawei Du, Lei Li, Zhiliang Jia, Dacheng Xie, Zhaoshen Li, Keping Xie
The serine/threonine kinase STK33 has been implicated in cancer cell proliferation. Here we provide evidence of a critical role for STK33 in the pathogenesis and metastatic progression of pancreatic ductal adenocarcinoma (PDAC). STK33 expression in PDAC was regulated by the hypoxia-inducible transcription factor HIF-1α. In human PDAC specimens, STK33 was overexpressed and associated with poor prognosis. Enforced STK33 expression promoted PDAC proliferation, migration, invasion and tumor growth, whereas STK33 depletion exerted opposing effects...
October 16, 2017: Cancer Research
https://www.readbyqxmd.com/read/29036786/pancreatic-cancer-and-associated-exosomes
#2
Chengfei Zhao, Feng Gao, Shaohuang Weng, Qicai Liu
Pancreatic cancers with poor prognosis are highly malignant, readily metastatic and of immune tolerance, mainly due to delayed detection. The metastatic progression and immune tolerance of pancreatic cancer is greatly attributed to the intercellular communication. However, exosomes are deemed to be the most important tool of intercellular communicators. Thus, we present a review of pancreatic cancer and exosomes in this article. We intensively summarize the progress of early pancreatic cancer and the relationship of the proliferation, progression and metastasis of pancreatic cancer and pancreatic cancer-derived exosomes, and propose new ideas of the study of pancreatic cancer...
September 29, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/29035014/nationwide-trends-in-chemotherapy-use-and-survival-of-elderly-patients-with-metastatic-pancreatic-cancer
#3
Lydia G M van der Geest, Nadia Haj Mohammad, Marc G H Besselink, Valery E P P Lemmens, Johanneke E A Portielje, Hanneke W M van Laarhoven, J Hanneke W Wilmink
Despite an aging population and underrepresentation of elderly patients in clinical trials, studies on elderly patients with metastatic pancreatic cancer are scarce. This study investigated the use of chemotherapy and survival in elderly patients with metastatic pancreatic cancer. From the Netherlands Cancer Registry, all 9407 patients diagnosed with primary metastatic pancreatic adenocarcinoma in 2005-2013 were selected to investigate chemotherapy use and overall survival (OS), using Kaplan-Meier and Cox proportional hazard regression analyses...
October 16, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/29029495/metadherin-promotes-metastasis-by-supporting-putative-cancer-stem-cell-properties-and-epithelial-plasticity-in-pancreatic-cancer
#4
Kensuke Suzuki, Shigetsugu Takano, Hideyuki Yoshitomi, Hitoe Nishino, Shingo Kagawa, Hiroaki Shimizu, Katsunori Furukawa, Masaru Miyazaki, Masayuki Ohtsuka
Pancreatic ductal adenocarcinoma (PDAC) has a high metastatic potential. However, the mechanism of metastatic colonization in PDAC remains poorly understood. Metadherin (MTDH) has emerged in recent years as a crucial mediator of metastasis in several cancer types, although the biological role of MTDH in PDAC has not been investigated. Here, we demonstrated the functional roles of MTDH in PDAC progression, especially focusing on the metastatic cascade. In vitro studies showed that MTDH provides cancer stem cell (CSC) properties in metastatic PDAC cells and contributes to anoikis resistance with epithelial characteristics in PDAC cells...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29025990/-177-lu-3bp-227-for-neurotensin-receptor-1-targeted-therapy-of-metastatic-pancreatic-adenocarcinoma-first-clinical-results
#5
Richard P Baum, Aviral Singh, Christiane Schuchardt, Harshad Rajaram Kulkarni, Ingo Klette, Stefan Wiessalla, Frank Osterkamp, Ulrich Reineke, Christiane Smerling
Neurotensin receptor 1 (NTR1) is overexpressed in ductal pancreatic adenocarcinoma, which is still one of the deadliest cancers with a very poor prognosis. Eligible patients were offered radiopharmaceutical treatment with the novel NTR1 antagonist (177)Lu-3BP-227 as salvage therapy. Methods: Six patients with confirmed ductal pancreatic adenocarcinoma who had exhausted all other treatment options received (177)Lu-3BP-227 for evaluation of NTR1 expression in vivo. Three patients received treatment activities between 5...
October 12, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29016614/patterns-and-rates-of-abdominal-lymphatic-metastasis-following-esophageal-carcinoma
#6
Junqiang Chen, Wenjie Cai, Yu Lin, Yuanmei Chen, Qingfeng Zheng, Jianji Pan, Chuanben Chen
AIM: To determine the rate of abdominal lymph node metastasis after radical surgery for esophageal cancer and define the radiotherapy target area. METHODS: Of the 1593 patients who underwent R0 radical esophagectomy for thoracic esophageal squamous cell carcinoma (TE-SCC), 148 developed abdominal lymph node (LN) metastases within three years of surgery. During that time interval, patients were examined by various imaging methods (enhanced computer tomography, magnetic resonance imaging, and positron emission tomography-CT) at set time points...
2017: PloS One
https://www.readbyqxmd.com/read/28993418/a-genetic-roadmap-of-pancreatic-cancer-still-evolving
#7
REVIEW
Faiyaz Notta, Stephan A Hahn, Francisco X Real
A diagnosis of pancreatic ductal adenocarcinoma (PDA) is often fatal. PDA is widely recognised as one of the 'incurable cancers' because therapies against this tumour type are generally ineffective. The fatal nature of this tumour is due to its aggressive clinical course. Pancreatic cancer commonly presents at the metastatic stage; even in cases where tumours are localised to the pancreas at diagnosis, metastatic seeds have often been invariably been spawned off, frustrating surgical attempts to cure the cancer...
October 9, 2017: Gut
https://www.readbyqxmd.com/read/28989542/cross-over-comparison-and-new-chemotherapy-regimens-in-metastatic-pancreatic-cancer
#8
REVIEW
Markus Kieler, Matthias Unseld, Daniela Bianconi, Gerald W Prager
Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) is still one of the most lethal malignant diseases with a devastating 5‑year overall survival of only 4-5%. Indeed, long-term survival was not affected by the introduction of new systemic cytotoxic chemotherapies which remain the key cornerstone in the treatment of metastatic PDAC. In the first-line setting, FOLFIRINOX based upon the results of the PRODIGE/ACCORD trial and gemcitabine with albumin-bound paclitaxel (GNP) based upon the MPACT trial have both been approved as therapeutic options for patients with no significant comorbidities and good performance status...
2017: Memo
https://www.readbyqxmd.com/read/28982867/impact-of-nab-paclitaxel-based-second-line-chemotherapy-in-metastatic-pancreatic-cancer
#9
REVIEW
Neelakanta Dadi, Melissa Stanley, Safi Shahda, Bert H O'Neil, Amikar Sehdev
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with median survival of 20% at 1 year. We conducted a retrospective study to assess the efficacy and tolerability of nab-paclitaxel (NP)-based second-line chemotherapy in metastatic PDAC. PATIENTS AND METHODS: The Indiana University Simon Cancer Center pancreatic cancer program was used to identify patients with metastatic PDAC who received any second-line chemotherapy. Demographic, clinical and outcomes data were collected by manual chart abstraction...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28982112/lymph-node-metastases-in-resected-pancreatic-ductal-adenocarcinoma-predictors-of-disease-recurrence-and-survival
#10
Vicente Morales-Oyarvide, Douglas A Rubinson, Richard F Dunne, Margaret M Kozak, Justin L Bui, Chen Yuan, Zhi Rong Qian, Ana Babic, Annacarolina Da Silva, Jonathan A Nowak, Natalia Khalaf, Lauren K Brais, Marisa W Welch, Caitlin L Zellers, Kimmie Ng, Daniel T Chang, Rebecca A Miksad, Andrea J Bullock, Jennifer F Tseng, Richard S Swanson, Thomas E Clancy, David C Linehan, Jennifer J Findeis-Hosey, Leona A Doyle, Jason L Hornick, Shuji Ogino, Charles S Fuchs, Aram F Hezel, Albert C Koong, Brian M Wolpin
BACKGROUND: Few studies have simultaneously assessed the prognostic value of the multiple classification systems for lymph node (LN) metastases in resected pancreatic ductal adenocarcinoma (PDAC). METHODS: In 600 patients with resected PDAC, we examined the association of LN parameters (AJCC 7th and 8th editions, LN ratio (LNR), and log odds of metastatic LN (LODDS)) with pattern of recurrence and patient survival using logistic regression and Cox proportional hazards regression, respectively...
October 5, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28982109/retrospective-analysis-of-ca19-9-decrease-in-patients-with-metastatic-pancreatic-carcinoma-treated-with-folfirinox-or-gemcitabine-in-a-randomized-phase-iii-study-accord11-prodige4
#11
Marie Robert, Marta Jarlier, Sophie Gourgou, Françoise Desseigne, Marc Ychou, Olivier Bouché, Beata Juzyna, Thierry Conroy, Jaafar Bennouna
OBJECTIVES: Carbohydrate antigen 19-9 (CA19-9) is a sensitive and specific serum marker in pancreatic cancer. Our retrospective analysis aims to evaluate CA19-9 decrease in patients with metastatic pancreatic cancer treated in ACCORD11/PRODIGE4 (FOLFIRINOX vs. gemcitabine). METHODS: A total of 342 patients were treated. CA19-9 was measured at 8 weeks (±2) in 160 patients from a total of 282 with abnormal CA19-9 values at baseline (gemcitabine arm, n = 75; FOLFIRINOX arm, n = 85)...
October 6, 2017: Oncology
https://www.readbyqxmd.com/read/28980060/phase-i-study-of-a-chloroquine-gemcitabine-combination-in-patients-with-metastatic-or-unresectable-pancreatic-cancer
#12
Panagiotis Samaras, Marina Tusup, Thi Dan Linh Nguyen-Kim, Burkhardt Seifert, Helga Bachmann, Roger von Moos, Alexander Knuth, Steve Pascolo
PURPOSE: Following a previously published pre-clinical validation, this phase I study evaluated the safety, maximum tolerated dose, anti-tumour activity and immune status of a gemcitabine-chloroquine combination as a first- or late-line treatment in patients with metastatic or unresectable pancreatic cancer. METHODS: In this 3 + 3 dose escalation study, patients received a single weekly standard dose of intravenous gemcitabine, followed by single weekly oral intake of 100, 200 or 300 mg of chloroquine...
October 4, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28979117/triple-functional-albumin-based-nanoparticles-for-combined-chemotherapy-and-photodynamic-therapy-of-pancreatic-cancer-with-lymphatic-metastases
#13
Xinzhe Yu, Wenwen Zhu, Yang Di, Jichun Gu, Zhongyi Guo, Hengchao Li, Deliang Fu, Chen Jin
Lymphatic metastasis is the major metastatic pattern of pancreatic cancer and considered as an independent risk factor of survival. However, there is still no effective way for the diagnosis and treatment for lymphatic metastases of pancreatic cancer. In this study, using albumin as a carrier of gemcitabine (Gem), further modified by pyropheophorbide-a, we have designed and synthesized a nanoparticle (NP) compound named "pheophorbide-a (P@)-Gem-human serum albumin (HSA)-NPs". By utilization of its tracer ability of lymphatic metastases, which is triggered by near-infrared irradiation and its visible dying ability, the compound is used for drug delivery tracking, meanwhile as a treating drug, as well as the combined effect of photodynamic therapy and chemotherapy...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/28978088/set-contributes-to-the-epithelial-mesenchymal-transition-of-pancreatic-cancer
#14
Hardik R Mody, Sau Wai Hung, Kineta Naidu, Haesung Lee, Caitlin A Gilbert, Toan Thanh Hoang, Rakesh K Pathak, Radhika Manoharan, Shanmugam Muruganandan, Rajgopal Govindarajan
Pancreatic cancer has a devastating prognosis due to 80-90% of diagnostic cases occurring when metastasis has already presented. Activation of the epithelial-mesenchymal transition (EMT) is a prerequisite for metastasis because it allows for the dissemination of tumor cells to blood stream and secondary organs. Here, we sought to determine the role of SET oncoprotein, an endogenous inhibitor of PP2A, in EMT and pancreatic tumor progression. Among the two major isoforms of SET (isoform 1 and isoform 2), higher protein levels of SET isoform 2 were identified in aggressive pancreatic cancer cell lines...
September 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28977895/silencing-igfbp-2-decreases-pancreatic-cancer-metastasis-and-enhances-chemotherapeutic-sensitivity
#15
Huan Liu, Le Li, Hua Chen, Rui Kong, Shangha Pan, Jisheng Hu, Yongwei Wang, Yilong Li, Bei Sun
Pancreatic cancer has remained one of the most devastating and lethal malignancies characterized by local invasion, distant metastasis and a high degree of chemoresistance. Insulin-like growth factor binding protein 2 (IGFBP-2) is a member of the IGFBP family of proteins, and it is highly expressed in pancreatic cancer patients' serum and tumor tissues. IGFBP-2 also mediates tumor cell growth, invasion and resistance, while the mechanisms remain unclear. In this study, we sought to determine the impact of IGFBP-2 expression on pancreatic cancer tumorigenesis and metastasis in vitro and in vivo...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28975822/multimodality-management-of-borderline-resectable-pancreatic-neuroendocrine-tumors-report-of-a-single-institution-experience
#16
Chenwi M Ambe, Phuong Nguyen, Barbara A Centeno, Junsung Choi, Jonathan Strosberg, Larry Kvols, Pamela Hodul, Sarah Hoffe, Mokenge P Malafa
BACKGROUND: Pancreatic neuroendocrine tumors (PanNETs) constitute approximately 3% of pancreatic neoplasms. Like patients with pancreatic ductal adenocarcinoma (PDAC), some of these patients present with "borderline resectable disease." For these patients, an optimal treatment approach is lacking. We report our institution's experience with borderline resectable PanNETs using multimodality treatment. METHODS: We identified patients with borderline resectable PanNETs who had received neoadjuvant therapy at our institution between 2000 and 2013...
October 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28974895/body-mass-index-does-not-affect-the-survival-of-pancreatic-cancer-patients
#17
Qing-Long Jiang, Cheng-Feng Wang, Yan-Tao Tian, Huang Huang, Shui-Sheng Zhang, Dong-Bing Zhao, Jie Ma, Wei Yuan, Yue-Min Sun, Xu Che, Jian-Wei Zhang, Yun-Mian Chu, Ya-Wei Zhang, Ying-Tai Chen
AIM: To evaluate the association of body mass index (BMI) with the overall survival of pancreatic ductal adenocarcinoma (PDAC) patients. METHODS: A retrospective analysis of PDAC patients diagnosed in the National Cancer Center of China between January 1999 and December 2014 was performed. These patients were categorized into four BMI groups (< 18.5, 18.5-22.9, 23-27.4 and ≥ 27.5 kg/m(2)). χ(2) tests for comparison of the proportions of categorical variables, and Student's t-test or Mann-Whitney test for continuous variables were employed...
September 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28972449/targeting-rock-activity-to-disrupt-and-prime-pancreatic-cancer-for-chemotherapy
#18
Claire Vennin, Nicola Rath, Marina Pajic, Michael F Olson, Paul Timpson
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease; the identification of novel targets and development of effective treatment strategies are urgently needed to improve patient outcomes. Remodeling of the pancreatic stroma occurs during PDAC development, which drives disease progression and impairs responses to therapy. The actomyosin regulatory ROCK1 and ROCK2 kinases govern cell motility and contractility, and have been suggested to be potential targets for cancer therapy, particularly to reduce the metastatic spread of tumor cells...
October 3, 2017: Small GTPases
https://www.readbyqxmd.com/read/28969005/pancreatic-cancer-derived-exosomes-promote-tumor-metastasis-and-liver-pre-metastatic-niche-formation
#19
Zeqian Yu, Susu Zhao, Long Ren, Lishan Wang, Zhangjun Chen, Robert M Hoffman, Jiahua Zhou
Exosomes play important roles in cell-cell communication, and are likely mediators of the metastatic cascade in cancer. This study examined the role of exosomes in pancreatic cancer cell adhesion, migration, and invasion. We isolated and purified exosomes from two isogenic pancreatic cancer cell lines with different metastatic potentials. Uptake of exosomes from highly metastatic Panc02-H7 cells decreased adhesion and increased migration and invasion capacity in weakly metastatic Panc02 cells in vitro. Exosomes from highly metastatic pancreatic cancer cells induced liver pre-metastatic niche formation in naïve mice and promoted primary tumor growth and liver metastasis in vivo...
September 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28961832/gemcitabine-combined-with-the-monoclonal-antibody-nimotuzumab-is-an-active-first-line-regimen-in-kras-wildtype-patients-with-locally-advanced-or-metastatic-pancreatic-cancer-a-multicenter-randomized-phase-iib-study
#20
B Schultheis, D Reuter, M P Ebert, J Siveke, A Kerkhoff, W E Berdel, R Hofheinz, D M Behringer, W E Schmidt, E Goker, S De Dosso, M Kneba, S Yalcin, F Overkamp, F Schlegel, M Dommach, R Rohrberg, T Steinmetz, M Bulitta, D Strumberg
Background: This randomized study was designed to investigate the superiority of gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth factor receptor monoclonal antibody, compared with gem plus placebo as first-line therapy in patients with advanced pancreatic cancer. Patients and methods: Patients with previously untreated, unresectable, locally advanced or metastatic pancreatic cancer were randomly assigned to receive gem: 1000 mg/m2, 30-min i...
October 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
31154
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"